LIVIVO - Search results -

Search results

Result 1 - 10 of total 27

Search options

Article ; Online: Renal osteodystrophy and aging.

Sherrard, Donald J

2009 Volume 29, Issue 6, Page(s) 636–642

Abstract: The bone disease seen in our aging dialysis population is a complex mixture of osteoporosis and renal osteodystrophy. Attention must be paid to both of these issues. Hip fractures are increased with aging and this increase is further aggravated by renal ... ...

Abstract	The bone disease seen in our aging dialysis population is a complex mixture of osteoporosis and renal osteodystrophy. Attention must be paid to both of these issues. Hip fractures are increased with aging and this increase is further aggravated by renal failure. Preventive management with Vitamin D and bisphosphonates is reviewed.
MeSH term(s)	Aged ; Aging ; Bone Density Conservation Agents/adverse effects ; Chronic Kidney Disease-Mineral and Bone Disorder/complications ; Diphosphonates/adverse effects ; Exercise Therapy ; Female ; Hip Fractures/etiology ; Hip Fractures/prevention & control ; Humans ; Kidney Failure, Chronic/complications ; Male ; Middle Aged ; Vitamin D/therapeutic use
Chemical Substances	Bone Density Conservation Agents ; Diphosphonates ; Vitamin D (1406-16-2)
Language	English
Publishing date	2009-11
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	604652-6
ISSN	1558-4488 ; 0270-9295
ISSN (online)	1558-4488
ISSN	0270-9295
DOI	10.1016/j.semnephrol.2009.07.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 784: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book: Practical fluids and electrolytes

Krieger, John N. / Sherrard, Donald J.

1991

Author's details	John N. Krieger ; Donald J. Sherrard
Keywords	Acid-Base Imbalance ; Kidney / physiology ; Water-Electrolyte Balance ; Water-Electrolyte Imbalance ; Elektrolythaushaltstörung ; Säure-Base-Gleichgewicht
Subject	Säure-Base-Haushalt ; Säure-Basen-Gleichgewicht ; Säure-Basen-Status ; Elektrolythaushaltsstörung ; Wasserhaushaltsstörung ; Elektrolytstörung
Size	XII, 242 S. : Ill., graph. Darst.
Edition	1. [Dr.]
Publisher	Appleton & Lange
Publishing place	East Norwalk, Conn. u.a.
Publishing country	Great Britain
Document type	Book
HBZ-ID	HT003945573
ISBN	0-8385-2621-7 ; 978-0-8385-2621-7
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
1991 A 5624	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Manipulating the calcium receptor.

Sherrard, Donald J

Journal of the American Society of Nephrology : JASN

2002 Volume 13, Issue 4, Page(s) 1124–1125

MeSH term(s)	Bone Diseases/drug therapy ; Calcium-Binding Proteins/metabolism ; Humans ; Hyperparathyroidism/drug therapy ; Parathyroid Hormone/antagonists & inhibitors
Chemical Substances	Calcium-Binding Proteins ; Parathyroid Hormone
Language	English
Publishing date	2002-04
Publishing country	United States
Document type	Comment ; Editorial ; Review
ZDB-ID	1085942-1
ISSN	1533-3450 ; 1046-6673
ISSN (online)	1533-3450
ISSN	1046-6673
DOI	10.1681/ASN.V1341124
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3344: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury.

Przkora, Rene / Herndon, David N / Sherrard, Donald J / Chinkes, David L / Klein, Gordon L

Bone

2007 Volume 41, Issue 2, Page(s) 297–302

Abstract: We have previously shown that pamidronate, when given within 10 days of burn injury, preserves lumbar spine bone mineral content from admission to discharge in 6-8 weeks and at 6 months increases both lumbar spine and total body bone mineral content (BMC) ...

Abstract	We have previously shown that pamidronate, when given within 10 days of burn injury, preserves lumbar spine bone mineral content from admission to discharge in 6-8 weeks and at 6 months increases both lumbar spine and total body bone mineral content (BMC) over placebo. We followed patients unblinded after 6 months every 3 months up to 2 years post-burn to see if the effects of pamidronate were sustained. Additionally, we assessed bone remodeling at 1 year post-burn by iliac crest bone biopsy. We enrolled 57 subjects who were initially randomized to pamidronate (n=32) and placebo (n=25). After 2 years, 21 subjects (pamidronate=8, placebo=13) remained. Analysis of bone densitometry by dual energy X-ray absorptiometry revealed an effect of both treatment (p<0.012 for total body BMC, p<0.001 for lumbar spine BMC, p<0.014 for lumbar spine bone area and p<0.003 for lumbar spine bone density (BMD)) and time (p<0.0003 on total body BMC, p<0.001 on lumbar spine BMC, p<0.001 on lumbar spine bone area, and no significant difference on lumbar spine BMD). There was no interaction between treatment and time. Results for bone histomorphometry revealed no effect of treatment on either static or dynamic parameters but did show an effect of time on osteoid area (p=0.004, surface p<0.001, and width, p<0.001). We conclude that acute administration of pamidronate resulted in sustained therapeutic effect on bone and that this type of administration may serve as a useful adjunct to other therapies in the preservation and augmentation of bone mass following severe burns.
MeSH term(s)	Bone Density/drug effects ; Bone Density Conservation Agents/pharmacology ; Bone Density Conservation Agents/therapeutic use ; Burns/drug therapy ; Child ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Humans ; Lumbar Vertebrae/anatomy & histology ; Lumbar Vertebrae/chemistry ; Lumbar Vertebrae/metabolism ; Lumbar Vertebrae/pathology
Chemical Substances	Bone Density Conservation Agents ; Diphosphonates ; pamidronate (OYY3447OMC)
Language	English
Publishing date	2007-08
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	632515-4
ISSN	1873-2763 ; 8756-3282
ISSN (online)	1873-2763
ISSN	8756-3282
DOI	10.1016/j.bone.2007.04.195
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 1571: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 332: Show issues

Order via subito

Details ▾

Article: Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy.

Goodman, William G / Jüppner, Harald / Salusky, Isidro B / Sherrard, Donald J

Kidney international

2003 Volume 63, Issue 1, Page(s) 1–11

Abstract: Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Reliable measurements of parathyroid hormone (PTH) concentrations in serum or plasma are critical for the appropriate diagnosis and management of patients with ... ...

Abstract	Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Reliable measurements of parathyroid hormone (PTH) concentrations in serum or plasma are critical for the appropriate diagnosis and management of patients with renal osteodystrophy. With the introduction of second generation immunometric assays for PTH, it is now possible to measure exclusively full-length, biologically active PTH(1-84). In contrast, first generation immunometric assays that have been used widely for many years detect not only PTH(1-84), but also other large amino-terminally-truncated, PTH-derived peptides. This development will require a careful re-evaluation of PTH measurements, as determined by either first or second generation immunometric assays, and their relationship to bone histology and bone remodeling rates in patients with end-stage renal disease (ESRD). Such information is essential for proper clinical management, but only limited bone biopsy data are available to guide the interpretation of PTH results using second generation PTH assays. The different performance characteristics of first and second generation immunometric PTH assays also makes it possible to quantify the plasma levels of amino-terminally-truncated, PTH-derived peptides, which may accumulate disproportionately in patients with ESRD. Recent experimental evidence indicates that one or more of these peptides can modify bone cell activity and skeletal remodeling, possibly by interacting with a PTH receptor distinct from the type I PTH receptor that binds to the amino-terminal portion of PTH and mediates the classical biological actions of the hormone. The putative C-PTH receptor interacts with mid- and/or carboxyterminal regions of PTH and other amino-terminally-truncated PTH-derived peptides; signaling through it may contribute to the skeletal resistance to PTH that characterizes ESRD. The current review discusses certain aspects of the molecular structure of PTH and its interaction with various receptors, briefly comments about selected components of PTH secretion, highlights recent technical advances in PTH assays, and summarizes the effects of various PTH-derived peptides on bone cells and on skeletal metabolism.
MeSH term(s)	Chronic Kidney Disease-Mineral and Bone Disorder/blood ; Chronic Kidney Disease-Mineral and Bone Disorder/etiology ; Humans ; Immunoassay ; Kidney Failure, Chronic/complications ; Parathyroid Hormone/analysis ; Parathyroid Hormone/blood
Chemical Substances	Parathyroid Hormone
Language	English
Publishing date	2003-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S. ; Review
ZDB-ID	120573-0
ISSN	1523-1755 ; 0085-2538
ISSN (online)	1523-1755
ISSN	0085-2538
DOI	10.1046/j.1523-1755.2003.00700.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 797: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Serum phosphate levels and mortality risk among people with chronic kidney disease.

Kestenbaum, Bryan / Sampson, Joshua N / Rudser, Kyle D / Patterson, Donald J / Seliger, Stephen L / Young, Bessie / Sherrard, Donald J / Andress, Dennis L

Journal of the American Society of Nephrology : JASN

2005 Volume 16, Issue 2, Page(s) 520–528

Abstract: Elevated serum phosphate levels have been linked with vascular calcification and mortality among dialysis patients. The relationship between phosphate and mortality has not been explored among patients with chronic kidney disease (CKD). A retrospective ... ...

Abstract	Elevated serum phosphate levels have been linked with vascular calcification and mortality among dialysis patients. The relationship between phosphate and mortality has not been explored among patients with chronic kidney disease (CKD). A retrospective cohort study was conducted from eight Veterans Affairs' Medical Centers located in the Pacific Northwest. CKD was defined by two continuously abnormal outpatient serum creatinine measurements at least 6 mo apart between 1999 and 2002. Patients who received chronic dialysis, those with a present or previous renal transplant, and those without a recent phosphate measurement were excluded. The primary end point was all-cause mortality. Secondary end points were acute myocardial infarction and the combined end point of myocardial infarction plus death. A total of 95,619 veterans with at least one primary care or internal medicine clinic contact from a Northwest VA facility and two or more outpatient measurements of serum creatinine, at least 6 mo apart, between January 1, 1999, and December 31, 2002, were identified. From this eligible population, 7021 patients met our definition of CKD. After exclusions, 6730 CKD patients were available for analysis, and 3490 had a serum phosphate measurement during the previous 18 mo. After adjustment, serum phosphate levels >3.5 mg/dl were associated with a significantly increased risk for death. Mortality risk increased linearly with each subsequent 0.5-mg/dl increase in serum phosphate levels. Elevated serum phosphate levels were independently associated with increased mortality risk among this population of patients with CKD.
MeSH term(s)	Age Distribution ; Aged ; Aged, 80 and over ; Biomarkers ; Calcium Phosphates/blood ; Cause of Death ; Cohort Studies ; Female ; Humans ; Kidney Failure, Chronic/diagnosis ; Kidney Failure, Chronic/mortality ; Kidney Failure, Chronic/therapy ; Kidney Function Tests ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Renal Dialysis/adverse effects ; Renal Dialysis/methods ; Retrospective Studies ; Risk Assessment ; Sensitivity and Specificity ; Severity of Illness Index ; Sex Distribution ; Survival Analysis
Chemical Substances	Biomarkers ; Calcium Phosphates
Language	English
Publishing date	2005-02
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	1085942-1
ISSN	1533-3450 ; 1046-6673
ISSN (online)	1533-3450
ISSN	1046-6673
DOI	10.1681/ASN.2004070602
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3344: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Calcium channel blocker use and mortality among patients with end-stage renal disease.

Kestenbaum, Bryan / Gillen, Daniel L / Sherrard, Donald J / Seliger, Steven / Ball, Adrianne / Stehman-Breen, Catherine

Kidney international

2002 Volume 61, Issue 6, Page(s) 2157–2164

Abstract: Background: Patients on dialysis suffer from alarming rates of cardiovascular disease. While calcium channel blockers (CCBs) are prescribed widely to patients with end-stage renal disease (ESRD) for the treatment of hypertension, the long-term outcomes ... ...

Abstract	Background: Patients on dialysis suffer from alarming rates of cardiovascular disease. While calcium channel blockers (CCBs) are prescribed widely to patients with end-stage renal disease (ESRD) for the treatment of hypertension, the long-term outcomes associated with the use of these medications are not known. We sought to determine the association between CCB use and mortality among a cohort of ESRD patients. Methods: Data were utilized from the United States Renal Data System Dialysis Morbidity and Mortality Wave II, a randomly selected prospective cohort of 4065 ESRD patients who began dialysis in 1996. Clinical data, including medication information, were collected 60 days after the start of dialysis. Subsequent survival status and cause of death were ascertained. The Cox proportional hazards model was used to estimate the relative risk of death associated with CCB use. Results: Data from 3716 patients (91.4%) were available for analysis. Fifty-one percent of the study patients were prescribed a CCB. The use of a CCB was associated with a 21% lower risk of total mortality (RR 0.79, CI 0.69 to 0.90) and a 26% lower risk of cardiovascular specific mortality (RR 0.74, CI 0.60 to 0.91). For patients with pre-existing cardiovascular disease, CCB use was associated with a 23% (RR 0.77, CI 0.65 to 0.91) and 32% (RR 0.68, CI 0.53 to 0.87) lower risk of total and cardiovascular mortality, respectively. Conclusion: After controlling for known risk factors and potential confounders, CCBs were found to be associated with a lower risk of mortality among ESRD patients.
MeSH term(s)	Adult ; Aged ; Calcium Channel Blockers/therapeutic use ; Cardiovascular Diseases/mortality ; Cohort Studies ; Female ; Humans ; Kidney Failure, Chronic/drug therapy ; Kidney Failure, Chronic/mortality ; Male ; Middle Aged ; Proportional Hazards Models ; Risk Assessment
Chemical Substances	Calcium Channel Blockers
Language	English
Publishing date	2002-06
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	120573-0
ISSN	1523-1755 ; 0085-2538
ISSN (online)	1523-1755
ISSN	0085-2538
DOI	10.1046/j.1523-1755.2002.00355.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 797: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study.

Klein, Gordon L / Wimalawansa, Sunil J / Kulkarni, Gayathri / Sherrard, Donald J / Sanford, Arthur P / Herndon, David N

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

2005 Volume 16, Issue 6, Page(s) 631–635

Abstract: Bone loss is a known complication of severe burn injury. It is, in part, due to increased endogenous glucocorticoids that contribute to the reduction in bone formation and osteoblast differentiation, hypercalciuria secondary to hypoparathyroidism, and ... ...

Abstract	Bone loss is a known complication of severe burn injury. It is, in part, due to increased endogenous glucocorticoids that contribute to the reduction in bone formation and osteoblast differentiation, hypercalciuria secondary to hypoparathyroidism, and vitamin D deficiency. In this study we attempted to prevent post-burn bone loss by acute intravenous administration of the bisphosphonate pamidronate. We enrolled 43 children, with burns of > 40% total body surface area, in a randomized, double-blind, placebo-controlled study, administering the study drug within 10 days of burn injury and again 1 week later. Dual energy X-ray absorptiometry was performed prior to drug therapy, at hospital discharge and at 6 months post-burn. Urine specimens were obtained at baseline and discharge for determination of calcium and free deoxypyridinoline. Blood was obtained along with the urine specimens for measurement of intact parathyroid hormone (iPTH) and ionized calcium (Ca) levels. Following doxycycline labeling, intra-operative iliac crest bone biopsies were obtained, and bone histomorphometry was determined. At time of discharge there were no differences in total body bone mineral content (BMC), but lumbar spine BMC was significantly higher in the pamidronate group (P < 0.005). By 6 months post-burn the differences in lumbar spine BMC persisted, but, now, total body BMC was significantly higher in the pamidronate group (P < 0.05). Bone histomorphometry and levels of urine Ca and free deoxypyridinoline failed to show significant increases in bone formation or decreases in bone resorption. Pamidronate did not exacerbate the hypocalcemia in burn patients. In summary, acute intravenous pamidronate administration following burns may help to preserve bone mass, perhaps by inhibiting the glucocorticoid-induced apoptosis of osteoblasts and osteocytes.
MeSH term(s)	Absorptiometry, Photon ; Acute Disease ; Adolescent ; Amino Acids/urine ; Anti-Inflammatory Agents/therapeutic use ; Biomarkers/blood ; Biomarkers/urine ; Bone Density/drug effects ; Bone Resorption/physiopathology ; Bone Resorption/prevention & control ; Bone and Bones/physiopathology ; Burns/blood ; Burns/drug therapy ; Burns/physiopathology ; Calcium/blood ; Calcium/urine ; Chi-Square Distribution ; Child ; Child, Preschool ; Diphosphonates/therapeutic use ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Infusions, Intravenous ; Male ; Parathyroid Hormone/blood
Chemical Substances	Amino Acids ; Anti-Inflammatory Agents ; Biomarkers ; Diphosphonates ; Parathyroid Hormone ; deoxypyridinoline (90032-33-0) ; pamidronate (OYY3447OMC) ; Calcium (SY7Q814VUP)
Language	English
Publishing date	2005-06
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	1064892-6
ISSN	1433-2965 ; 0937-941X
ISSN (online)	1433-2965
ISSN	0937-941X
DOI	10.1007/s00198-004-1731-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3163: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Parathyroidectomy rates among United States dialysis patients: 1990-1999.

Kestenbaum, Bryan / Seliger, Stephen L / Gillen, Daniel L / Wasse, Haimanot / Young, Bessie / Sherrard, Donald J / Weiss, Noel S / Stehman-Breen, Catherine O

Kidney international

2004 Volume 65, Issue 1, Page(s) 282–288

Abstract: Background: Medical therapy for secondary hyperparathyroidism (SHPTH) has evolved considerably during the past decade. It is not known how changes in medical therapy might impact the parathyroidectomy (PTX) rate among dialysis patients. Relatively low ... ...

Abstract	Background: Medical therapy for secondary hyperparathyroidism (SHPTH) has evolved considerably during the past decade. It is not known how changes in medical therapy might impact the parathyroidectomy (PTX) rate among dialysis patients. Relatively low parathyroid hormone (PTH) levels have been found among elderly dialysis patients and those with diabetes. Clinical factors associated with differing PTX rates among United States dialysis patients have not been reported. We report PTX rates in the United States from 1990 to 1999 among persons with end-stage renal disease, accounting for changes in patient characteristics. Methods: Data from the United States Renal Database were utilized. Patients insured by Medicare or Medicaid and receiving renal replacement therapy between January 1, 1990, and December 31, 1999 were considered for analysis. PTX was determined by ICD-9 procedure codes. Multivariate Poisson models were used to estimate adjusted PTX rates. Results: The overall observed PTX rate in the study sample was 7.16 per 1000 person-years at risk. After a slight rise during the early 1990s, adjusted PTX rates declined by approximately 30% between 1995 and 1999. Adjusted PTX rates were higher among patients who were younger, female, nondiabetic, receiving peritoneal dialysis, and those with a longer cumulative duration of dialysis. Conclusion: PTX rates have recently decreased in the United States, independent of changes in patient characteristics. The effectiveness of medical therapy in targeting secondary hyperparathyroidism may be improving. Younger, nondiabetic patients with a longer cumulative dialysis burden are at particularly high risk for PTX.
MeSH term(s)	Aged ; Databases, Factual ; Female ; Humans ; Hyperparathyroidism, Secondary/epidemiology ; Hyperparathyroidism, Secondary/surgery ; Incidence ; Kidney Failure, Chronic/epidemiology ; Male ; Middle Aged ; Parathyroidectomy/statistics & numerical data ; Risk Factors ; United States/epidemiology
Language	English
Publishing date	2004-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	120573-0
ISSN	1523-1755 ; 0085-2538
ISSN (online)	1523-1755
ISSN	0085-2538
DOI	10.1111/j.1523-1755.2004.00368.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 797: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Survival following parathyroidectomy among United States dialysis patients.

Kestenbaum, Bryan / Andress, Dennis L / Schwartz, Stephen M / Gillen, Daniel L / Seliger, Stephen L / Jadav, Paresh R / Sherrard, Donald J / Stehman-Breen, Catherine

Kidney international

2004 Volume 66, Issue 5, Page(s) 2010–2016

Abstract: Background: Secondary hyperparathyroidism (SHPTH) is highly prevalent among persons with end-stage renal disease (ESRD). SHPTH has been linked to uremic bone disease, vascular calcification, and a higher risk of death. Parathyroidectomy (PTX) can ... ...

Abstract	Background: Secondary hyperparathyroidism (SHPTH) is highly prevalent among persons with end-stage renal disease (ESRD). SHPTH has been linked to uremic bone disease, vascular calcification, and a higher risk of death. Parathyroidectomy (PTX) can dramatically reduce parathyroid hormone (PTH) and phosphate levels; however, the relationship between PTX and survival is not known. Methods: We conducted an observational matched cohort study utilizing data from the United States Renal Database System (USRDS) in which 4558 patients undergoing a first PTX while on hemodialysis or peritoneal dialysis were individually matched by age, race, gender, cause of ESRD, dialysis duration, prior transplantation status, and dialysis modality to 4558 control patients who did not undergo PTX. Patients were followed from the date of PTX until they died or were lost to follow-up. Results: The 30-day postoperative mortality rate following PTX was 3.1%. Long-term relative risks of death among patients undergoing PTX were estimated to be 10% to 15% lower than those of matched control patients not undergoing surgery. Survival curves between the 2 groups crossed 587 days following PTX. Median survival was 53.4 months (95% CI: 51.2-56.4) in the PTX group, and 46.8 months (95% CI: 44.7-48.9) in the control group. Conclusion: PTX was associated with higher short-term, and lower long-term, mortality rates among U.S. patients receiving chronic dialysis. Measures to attenuate SHPTH may play an important role in reducing mortality among patients with end-stage renal disease.
MeSH term(s)	Adult ; Case-Control Studies ; Cohort Studies ; Databases, Factual ; Female ; Follow-Up Studies ; Humans ; Hyperparathyroidism, Secondary/etiology ; Hyperparathyroidism, Secondary/surgery ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/therapy ; Male ; Middle Aged ; Parathyroidectomy/mortality ; Renal Dialysis ; Risk ; Survival Analysis ; Time Factors ; United States
Language	English
Publishing date	2004-11
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	120573-0
ISSN	1523-1755 ; 0085-2538
ISSN (online)	1523-1755
ISSN	0085-2538
DOI	10.1111/j.1523-1755.2004.00972.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 797: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito